Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD6AJO)

• Drug Name: N6-CYCLOPENTYLADENOSINE Drug Info
• Synonyms: N6-Cyclopentyladenosine; 41552-82-3; n-cyclopentyladenosine; (2R,3R,4S,5R)-2-(6-(Cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Cyclopentyladenosine; CHEMBL68738; MLS000028368; N(6)-Cyclopentyladenosine; SMR000058639; (2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Adenosine, N-cyclopentyl-; UNII-7LG47VG1ID; 7LG47VG1ID; N6-CyclopentylAdo; n-cyclopentyl-adenosine; n6-cyclopentyl-adenosine; AC1LCWG1; Opera_ID_1056; GTPL380; MLS002153196; MLS001077332; SCHEMBL120481

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 657378
  CAS Number: CAS 41552-82-3
  TTD Drug ID: DMD6AJO
  VARIDT Drug ID: DR00860

Molecule-Related Drug Atlas

Drug(s) Targeting Solute carrier family 29 member 1 (SLC29A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[8]
Dilazep	DMOD5Y0	Discovery agent	N.A.	Investigative	[9]
S6-nitrobenzyl mercaptopurine riboside	DMIKJNL	Discovery agent	N.A.	Investigative	[10]
[3H]nitrobenzylmercaptopurine ribonucleoside	DM5TDFQ	Discovery agent	N.A.	Investigative	[11]
KF24345	DMK6SMW	Discovery agent	N.A.	Investigative	[12]
NBTGR	DMVF420	Discovery agent	N.A.	Investigative	[11]
9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine	DMNY5P1	Discovery agent	N.A.	Investigative	[13]
Nitrobenzylthioinosine	DM7F3RY	Discovery agent	N.A.	Investigative	[14]
6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine	DMPL5XV	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Adenylate cyclase (ADCY)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad5-AC6	DMQNFZE	Cardiac failure	BD10-BD13	Terminated	[15]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[16]
[3H]alphabeta-meATP	DMWV5C3	Discovery agent	N.A.	Investigative	[16]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]
2-hydroxy-17beta-estradiol	DMM9Z0B	Discovery agent	N.A.	Investigative	[17]
2,5-didesoxy-3-ATP	DM5CWM0	Discovery agent	N.A.	Investigative	[17]
		N. A.	N. A.		[18]
		N. A.	N. A.		[18]
		N. A.	N. A.		[18]
		N. A.	N. A.		[18]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[19]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[3]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[20]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[21]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[22]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[23]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[24]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[25]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[21]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[21]

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[26]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[27]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[28]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[29]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[30]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[31]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[3]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[32]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[33]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[34]

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[35]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[35]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[36]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[3]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[37]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[38]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[39]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[40]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[41]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[38]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[26]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[42]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[3]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[33]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[43]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[44]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[45]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[43]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[46]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[47]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Inhibitor	[2]
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[3]
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Inhibitor	[4]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[5]
Adenylate cyclase (ADCY)	TT2QM9D	NOUNIPROTAC	Inhibitor	[6]
Solute carrier family 29 member 1 (SLC29A1)	TTLXAKE	S29A1_HUMAN	Inhibitor	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 380).
• [2] 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53.
• [3] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [4] Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83.
• [5] Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprote... J Med Chem. 2005 Dec 29;48(26):8103-7.
• [6] Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors. J Med Chem. 1991 Dec;34(12):3388-90.
• [7] Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines. J Med Chem. 2005 Jan 13;48(1):321-9.
• [8] Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibit... J Med Chem. 2007 Aug 9;50(16):3906-20.
• [9] Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-merc... Mol Pharmacol. 2005 Mar;67(3):837-44.
• [10] Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1117).
• [12] Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazol... J Pharmacol Exp Ther. 2004 Mar;308(3):1083-93.
• [13] Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. J Med Chem. 2004 Oct 21;47(22):5441-50.
• [14] The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol. 2008 Nov;74(5):1372-80.
• [15] Unanticipated Signaling Events Associated with Cardiac Adenylyl Cyclase Gene Transfer. J Mol Cell Cardiol. 2011 May; 50(5): 751-758.
• [16] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [17] Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64.
• [18] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [19] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [20] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [21] 2011 Pipeline of Can-Fite BioPharm.
• [22] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [23] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [24] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [25] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [26] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [29] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [30] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [32] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [33] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [34] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [35] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [36] Clinical pipeline report, company report or official report of Klus Pharma
• [37] Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
• [38] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [39] Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
• [40] Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
• [41] GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
• [42] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [43] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [44] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [45] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [46] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [47] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.